Drug Profile
Polysaccharide K
Alternative Names: Krestin; Polysaccharide-K; PSKLatest Information Update: 10 Dec 2007
Price :
$50
*
At a glance
- Originator Kureha Corporation
- Developer Daiichi Sankyo Company; Kureha Corporation
- Class Antineoplastics; Glycoproteins; Proteoglycans
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Cancer
- Discontinued Herpes simplex virus infections
Most Recent Events
- 24 Jun 2018 Biomarkers information updated
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 25 Jun 1998 Launched for Cancer in Japan (PO)